1. Multi-targeted nanoarrays for early broad-spectrum detection of lung cancer based on blood biopsy of tumor exosomes.
- Author
-
Lian S, Wang Q, Liu Y, Lu Y, Huang L, Deng H, and Xie X
- Subjects
- Animals, Humans, Mice, Nanoparticles chemistry, Early Detection of Cancer methods, Biomarkers, Tumor blood, Aptamers, Nucleotide chemistry, Liquid Biopsy methods, Mice, Nude, Mice, Inbred BALB C, Cell Line, Tumor, Exosomes chemistry, Lung Neoplasms pathology, Lung Neoplasms blood, Lung Neoplasms diagnosis, Silicon Dioxide chemistry
- Abstract
Liquid biopsies utilizing tumor exosomes offer a noninvasive approach for cancer diagnosis. However, validation studies consistently report that in the early stages of cancer, the secretion of exosomes by cancer cells is relatively low, while bodily fluids exhibit a high abundance of other interfering biomolecules. Additionally, target mutations or differences in biomarker expression among various lung cancer subtypes may contribute to detection failures. In this study, we propose a targeted nanoarray-based early cancer diagnostic approach for multiple subtypes of lung cancer. The targeted nanoarray was constructed by modifying five targeting aptamers onto mesoporous silica nanoparticles through the conjugation between amino and carboxyl groups. The flow cytometry experiments demonstrated the specific recognition ability of the targeted nanoarray to tumor exosomes in PBS, even at biomarker expression levels as low as 1.5 %. Moreover, the TEM results indicated that the targeted nanoarray could isolate tumor exosomes in the blood of tumor-bearing mice. Furthermore, the targeted nanoarray could detect tumor exosomes in the blood of various lung cancer bearing mice, including at the early stages of cancer, which has just been established for 7 days. Overall, the targeted nanoarray represents a promising tool for the early detection of various subtypes of lung cancer., Competing Interests: Declaration of competing interest Xie Xiaodong is applying for a patent related to this work. The rest of the authors have no financial or non-financial competing interests., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF